Nature Reviews Neurology最新文献_第2页

High prevalence of hepatitis B in NMOSD 非传染性疾病中乙型肝炎的高发病率

IF 28.2 1区医学

Nature Reviews Neurology Pub Date : 2024-11-13 DOI: 10.1038/s41582-024-01037-8

Lisa Kiani

引用次数: 0

Glymphatic dysfunction in PD clinical progression 淋巴功能障碍与帕金森病临床进展的关系

IF 28.2 1区医学

Nature Reviews Neurology Pub Date : 2024-11-13 DOI: 10.1038/s41582-024-01040-z

Lisa Kiani

引用次数: 0

Immune responses influence sex differences in Alzheimer disease 免疫反应影响阿尔茨海默病的性别差异

IF 28.2 1区医学

Nature Reviews Neurology Pub Date : 2024-11-13 DOI: 10.1038/s41582-024-01044-9

Ian Fyfe

引用次数: 0

Parkinson disease therapy: current strategies and future research priorities 帕金森病治疗：当前战略和未来研究重点

IF 28.2 1区医学

Nature Reviews Neurology Pub Date : 2024-11-04 DOI: 10.1038/s41582-024-01034-x

Fabrizio Stocchi, Daniele Bravi, Aron Emmi, Angelo Antonini

{"title":"Parkinson disease therapy: current strategies and future research priorities","authors":"Fabrizio Stocchi, Daniele Bravi, Aron Emmi, Angelo Antonini","doi":"10.1038/s41582-024-01034-x","DOIUrl":"10.1038/s41582-024-01034-x","url":null,"abstract":"Parkinson disease (PD) is the fastest growing neurological disorder globally and poses substantial management challenges owing to progressive disability, emergence of levodopa-resistant symptoms, and treatment-related complications. In this Review, we examine the current state of research into PD therapies and outline future priorities for advancing our understanding and treatment of the disease. We identify two main research priorities for the coming years: first, slowing the progression of the disease through the integration of sensitive biomarkers and targeted biological therapies, and second, enhancing existing symptomatic treatments, encompassing surgical and infusion therapies, with the goal of postponing complications and improving long-term patient management. The path towards disease modification is impeded by the multifaceted pathophysiology and diverse mechanisms underlying PD. Ongoing studies are directed at α-synuclein aggregation, complemented by efforts to address specific pathways associated with the less common genetic forms of the disease. The success of these efforts relies on establishing robust end points, incorporating technology, and identifying reliable biomarkers for early diagnosis and continuous monitoring of disease progression. In the context of symptomatic treatment, the focus should shift towards refining existing approaches and fostering the development of novel therapeutic strategies that target levodopa-resistant symptoms and clinical manifestations that substantially impair quality of life. Parkinson disease (PD) poses substantial management challenges owing to progressive disability and emergence of levodopa-resistant symptoms and treatment-related complications. This Review examines the current state of research into symptomatic and disease-modifying PD therapies and outlines future priorities for advancing our understanding and treatment of the disease.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"20 12","pages":"695-707"},"PeriodicalIF":28.2,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142574393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Digitized Memory Clinic 数字化记忆诊所

IF 28.2 1区医学

Nature Reviews Neurology Pub Date : 2024-10-25 DOI: 10.1038/s41582-024-01033-y

Mathias Holsey Gramkow, Gunhild Waldemar, Kristian Steen Frederiksen

{"title":"The Digitized Memory Clinic","authors":"Mathias Holsey Gramkow, Gunhild Waldemar, Kristian Steen Frederiksen","doi":"10.1038/s41582-024-01033-y","DOIUrl":"10.1038/s41582-024-01033-y","url":null,"abstract":"Several major challenges, including an ageing population and declining workforce and the implementation of recent breakthrough therapies for Alzheimer disease, are prompting a necessary rethink of how people with neurodegenerative dementias are diagnosed and medically managed. Digital health technologies could play a pivotal part in this transformation, with new advances enabling the collection of millions of data points from a single individual. Possible applications include unobtrusive monitoring that aids early detection of disease and artificial intelligence-based health advice. To translate these advances to meaningful benefits for people living with a disease, technologies must be implemented within a system that retains the physician expert as a central figure in decision-making. This Perspective presents a new framework, termed the Digitized Memory Clinic, for the diagnostic pathway of neurodegenerative dementias that incorporates digital health technologies with currently available assessment tools, such as fluid and imaging biomarkers, in an interplay with the physician. The Digitized Memory Clinic will manage people across the entire disease spectrum, from the detection of risk factors for cognitive decline and the earliest symptoms to dementia, and will replace the present paradigm of a pure ‘brick-and-mortar’ memory clinic. Important ethical, legal and societal barriers associated with the implementation of digital health technologies in memory clinics need to be addressed. The envisioned Digitized Memory Clinic aims to improve diagnostics and enable precise disease-tracking prognostication for individuals with memory disorders and to open new possibilities, such as precision medicine for prevention and treatment. In this Perspective, the authors present the Digitized Memory Clinic, a new framework for the diagnostic pathway of neurodegenerative dementias that incorporates digital health technologies with currently available assessment tools, such as fluid and imaging biomarkers, in an interplay with the physician.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"20 12","pages":"738-746"},"PeriodicalIF":28.2,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142489365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Altered muscle cholesterol transport in ALS 渐冻人症中肌肉胆固醇转运的改变

IF 28.2 1区医学

Nature Reviews Neurology Pub Date : 2024-10-14 DOI: 10.1038/s41582-024-01029-8

Heather Wood

引用次数: 0

Lewy body pathology accelerates AD progression 路易体病理学加速了注意力缺失症的进展

IF 28.2 1区医学

Nature Reviews Neurology Pub Date : 2024-10-14 DOI: 10.1038/s41582-024-01028-9

Heather Wood

引用次数: 0

Engineered T cells show therapeutic potential for CNS injury 工程化 T 细胞显示出治疗中枢神经系统损伤的潜力

IF 28.2 1区医学

Nature Reviews Neurology Pub Date : 2024-10-14 DOI: 10.1038/s41582-024-01032-z

Lisa Kiani

引用次数: 0

Evidence for an NMOSD prodrome NMOSD 前驱症状的证据

IF 28.2 1区医学

Nature Reviews Neurology Pub Date : 2024-10-14 DOI: 10.1038/s41582-024-01030-1

Heather Wood

引用次数: 0

BCAS1+ oligodendrocytes aid remyelination in MS BCAS1+ 少突胶质细胞有助于多发性硬化症的髓鞘再形成

IF 28.2 1区医学

Nature Reviews Neurology Pub Date : 2024-10-14 DOI: 10.1038/s41582-024-01031-0

Heather Wood

引用次数: 0